AMP Increases its Hypothetical Position in ANTH Ahead of Phase 2 IgA Nephropathy Results

Today AMP increased its position in Anthera Pharmaceuticals by purchasing 8,389 shares at a share price of $1.49/share in a transaction totaling $12,500. Anthera is expected to report the results of its Phase 2 Blisibimod study in IgA nephropathy AMP by the end of Q3.

AMP has now allocated 2.91% of its hypothetical fund in Anthera with $37,500 invested.